Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials

An operationalized workflow paradigm is presented and validated with pilot subject data. This approach is reproducible with a high concordance rate between individual readers (kappa 0.73 [confidence interval 0.59-0.87; =<0.0001]) using a 5-point scale to assess [ F] labeled fluorodeoxyglucose met...

Full description

Saved in:

Bibliographic Details
Published in:	Drug design, development and therapy Vol. 11; pp. 1719 - 1728
Main Authors:	Van Heertum, Ronald L, Scarimbolo, Robert, Wolodzko, John G, Klencke, Barbara, Messmann, Richard, Tunc, Feza, Sokol, Levi, Agarwal, Rajan, Strafaci, James A, O'Neal, Michael
Format:	Journal Article
Language:	English
Published:	New Zealand Dove Medical Press Limited 01-01-2017 Taylor & Francis Ltd Dove Medical Press
Subjects:	Adult Aged Aged, 80 and over Blood diseases Bone marrow Cancer Care and treatment Clinical trials Clinical Trials as Topic - standards Cohort Studies Confidence intervals CT imaging Diagnosis Disease Female Fluorodeoxyglucose F18 Humans Image Interpretation, Computer-Assisted Lesions Lugano criteria Lymphoma Lymphoma - diagnostic imaging Lymphomas Male Medical imaging Medical research Middle Aged Molecular Imaging Neoplasm Staging Observer Variation Oncology oncology trials Original Research PET imaging Positron Emission Tomography Computed Tomography - standards Reproducibility of Results Research Design Transplants & implants Workflow Working groups United States > US oncology trials molecular imaging Lugano criteria lymphoma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	An operationalized workflow paradigm is presented and validated with pilot subject data. This approach is reproducible with a high concordance rate between individual readers (kappa 0.73 [confidence interval 0.59-0.87; =<0.0001]) using a 5-point scale to assess [ F] labeled fluorodeoxyglucose metabolic activity in lymphomatous lesions. These results suggest an operationally practical 5-point scale workflow paradigm for potential use in larger clinical trials evaluating lymphoma therapeutics.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1177-8881 1177-8881
DOI:	10.2147/DDDT.S136988